ID   B2R9S6_HUMAN            Unreviewed;       925 AA.
AC   B2R9S6;
DT   01-JUL-2008, integrated into UniProtKB/TrEMBL.
DT   01-JUL-2008, sequence version 1.
DT   27-MAR-2024, entry version 88.
DE   SubName: Full=cDNA, FLJ94537, highly similar to Homo sapiens MCF.2 cell line derived transforming sequence (MCF2), mRNA {ECO:0000313|EMBL:BAG36623.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG36623.1};
RN   [1] {ECO:0000313|EMBL:BAG36623.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAG36623.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Kaida T., Tsuchiya K., Iida Y.,
RA   Takayama Y., Murakawa K., Kanehori K., Andoh T., Kagawa N., Sato R.,
RA   Kawamura Y., Tanaka S., Kisu Y., Sugano S., Goshima N., Nomura N.,
RA   Isogai T.;
RT   "NEDO functional analysis of protein and research application project.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK313900; BAG36623.1; -; mRNA.
DR   RefSeq; NP_001165348.1; NM_001171877.1.
DR   RefSeq; NP_001165349.1; NM_001171878.1.
DR   RefSeq; NP_001165350.1; NM_001171879.1.
DR   RefSeq; NP_005360.3; NM_005369.4.
DR   AlphaFoldDB; B2R9S6; -.
DR   PeptideAtlas; B2R9S6; -.
DR   DNASU; 4168; -.
DR   GeneID; 4168; -.
DR   KEGG; hsa:4168; -.
DR   CTD; 4168; -.
DR   PharmGKB; PA30684; -.
DR   OrthoDB; 4244290at2759; -.
DR   BioGRID-ORCS; 4168; 9 hits in 773 CRISPR screens.
DR   GenomeRNAi; 4168; -.
DR   Genevisible; B2R9S6; HS.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IEA:InterPro.
DR   GO; GO:0048583; P:regulation of response to stimulus; IEA:UniProt.
DR   CDD; cd00160; RhoGEF; 1.
DR   CDD; cd00176; SPEC; 1.
DR   Gene3D; 1.20.58.60; -; 1.
DR   Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR001251; CRAL-TRIO_dom.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   PANTHER; PTHR22826:SF146; PROTO-ONCOGENE DBL; 1.
DR   PANTHER; PTHR22826; RHO GUANINE EXCHANGE FACTOR-RELATED; 1.
DR   Pfam; PF13716; CRAL_TRIO_2; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00621; RhoGEF; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00325; RhoGEF; 1.
DR   SMART; SM00150; SPEC; 1.
DR   SUPFAM; SSF48065; DBL homology domain (DH-domain); 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF46966; Spectrin repeat; 1.
DR   PROSITE; PS50191; CRAL_TRIO; 1.
DR   PROSITE; PS50010; DH_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   DOMAIN          13..88
FT                   /note="CRAL-TRIO"
FT                   /evidence="ECO:0000259|PROSITE:PS50191"
FT   DOMAIN          495..675
FT                   /note="DH"
FT                   /evidence="ECO:0000259|PROSITE:PS50010"
FT   DOMAIN          687..809
FT                   /note="PH"
FT                   /evidence="ECO:0000259|PROSITE:PS50003"
FT   COILED          244..274
FT                   /evidence="ECO:0000256|SAM:Coils"
SQ   SEQUENCE   925 AA;  107632 MW;  823BDF6E72F367EB CRC64;
     MAEANPRRGK MRFRRNAASF PGNLHLVLVL RPTSFLQRTF TDIGFWFSQE DFMLKLPVVM
     LSSVSDLLTY IDDKQLTPEL GGTLQYCHSE WIIFRNAIEN FALTVKEMAQ MLQSFGTELA
     ETELPDDIPS IEEILAIRAE RYHLLKNDIT AVTKEGKILL TNLEVPDTEG AVSSRLECHR
     QISGDWQTIN KLLTQVHDME TAFDGFWEKH QLKMEQYLQL WKFEQDFQQL VTEVEFLLNQ
     QAELADVTGT IAQVKQKIKK LENLDENSQE LLSKAQFVIL HGHKLAANHH YALDLICQRC
     NELRYLSDIL VNEIKAKRIQ LSRTFKMHKL LQQARQCCDE GECLLANQEI DKFQSKEDAQ
     KALQDIENFL EMALPFINYE PETLQYEFDV ILSPELKVQM KTIQLKLENI RSIFENQQAG
     FRNLADKHVR PIQFVVPTPE NLVTSGTPFF SSKQGKKTWR QNQSNLKIEV VPDCQEKRSS
     GPSSSLDNGN SLDVLKNHVL NELIQTERVY VRELYTVLLG YRAEMDNPEM FDLMPPLLRN
     KKDILFGNMA EIYEFHNDIF LSSLENCAHA PERVGPCFLE RKDDFQMYAK YCQNKPRSET
     IWRKYSECAF FQECQRKLKH RLRLDSYLLK PGQRITKYQL LLKELLKYSK DCEGSALLKK
     ALDAMLDLLK SVNDSMHQIA INGYIGNLNE LGKMIMQGGF SVWIGHKKGA TKMKDLARFK
     PMQRHLFLYE KAIVFCKRRV ESGEGSDRYP SYSFKHCWKM DEVGITEYVK GDNRKFEIWY
     GEKEEVYIVQ ASNVDVKMTW LKEIRNILLK QQELLTVKKR KQQDQLTERD KFQISLQQND
     EKQQGAFIST EETELEHTST VVEVCEAIAS VQAEANTVWT EASQSAEISE EPAEWSSNYF
     YPTYDEDEEE NRPLMRPVSE MALLY
//